Composition for regenerating normal tissue from fibrotic tissue

Patent metadata

Field	Value
Publication number	US-9408864-B2
Application number	US-201113813907-A
Country	US
Kind code	B2
Filing date	Aug 5, 2011
Priority date	Aug 5, 2010
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

First claim

The invention claimed is:

1. A method comprising identifying a human subject (1) having a fibrotic tissue that continually receives a fibrotic stimulus and (2) for whom regeneration of normal tissue from the fibrotic tissue is needed; and administering an effective amount of a pharmaceutical composition comprising a collagen-reducing substance to the subject, thereby differentiating stem cells into normal tissue cells in the fibrotic tissue and regenerating normal tissue from the fibrotic tissue in the subject while the fibrotic tissue is receiving the fibrotic stimulus.

2. A method comprising identifying a human subject (1) having a fibrotic tissue that continually receives a fibrotic stimulus and (2) for whom regeneration of normal tissue from the fibrotic tissue is needed; reducing collagen in a fibrotic tissue of the subject and/or a step of forming a space for cell growth and differentiation in a fibrotic tissue of the subject; and differentiating stem cells in the fibrotic tissue into normal tissue cells, thereby regenerating normal tissue from the fibrotic tissue while the fibrotic tissue is receiving the fibrotic stimulus.

3. The method according to claim 1 , wherein the collagen-reducing substance is selected from the group consisting of a suppressor of collagen production by collagen-producing cells, a promoter of collagen decomposition, and a suppressor of a collagen decomposition inhibitor.

4. The method according to claim 1 , wherein the pharmaceutical composition further comprises a targeting agent for collagen-producing cells in fibrotic tissue.

5. The method according to claim 1 , wherein the pharmaceutical composition further comprises a retinoid.

6. The method according to claim 3 , wherein the suppressor of collagen production by collagen-producing cells is selected from the group consisting of a TGFβ inhibitor, HGF or a substance promoting the production thereof, a PPARγ ligand, an angiotensin inhibitor, a PDGF inhibitor, relaxin or a substance promoting the production thereof, a substance that inhibits the production and secretion of an extracellular matrix component, a cell activity suppressor, a cell growth suppressor, and an apoptosis-inducing substance.

7. The method according to claim 3 , wherein the promoter of collagen decomposition is collagenase or a collagenase production promoter.

8. The method according to claim 3 , wherein the suppressor of a collagen decomposition inhibitor is a TIMP inhibitor.

Assignees

• Niitsu Yoshiro
• Yoneda Akihiro
• Ishiwatari Hirotoshi
• Nitto Denko Corp

Inventors

• Niitsu Yoshiro
• Yoneda Akihiro
• Ishiwatari Hirotoshi

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title